Brief: Petros Pharmaceuticals To Pursue 505(B)(2) Pathway For H-100, Company’S Novel Topical Investigational Treatment For Peyronie’S Disease Which Impacts More Than 1 In 10 Men In The Us
03/05/2022 14:32
May 3 (Reuters) - Petros Pharmaceuticals Inc PTPI.O :
* PETROS PHARMACEUTICALS TO PURSUE 505(B)(2) PATHWAY FOR
H-100,
COMPANY’S NOVEL TOPICAL INVESTIGATIONAL TREATMENT FOR PEYRONIE’S
DISEASE WHICH IMPACTS MORE THAN 1 IN 10 MEN IN THE US
Source text for Eikon: ID:nGNX89XNBQ
Further company coverage: PTPI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Petros Pharmaceuticals
See all newsBrief: Petros Pharmaceuticals Assigns All Assets To Pt Liquidation, For Benefit Of Creditors
Brief: Petros Pharmaceuticals’ STENDRA Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance
Brief: Petros Pharmaceuticals Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: Petros Pharmaceuticals Expands Online Distribution For Prescription STENDRA(R) Through New Agreement With Lemonaid Health
Brief: Petros Pharma Announces Partnership with Idea Evolver for Rx-to-OTC Switches & Digital Launch Solutions